Gamma Communications: Offer Update

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

FOR IMMEDIATE RELEASE

19 October 2026

RECOMMENDED FINAL* CASH OFFER

by

BRADBURY BIDCO LIMITED

(a newly incorporated company controlled by funds managed and/or advised by Epiris GP III Limited and its affiliates)

for

GAMMA COMMUNICATIONS PLC

to be effected by means of a Scheme of Arrangement

under Part 26 of the Companies Act 2006

ADJOURNMENT OF SHAREHOLDER MEETINGS AND NO INCREASE STATEMENT*

On 1 September 2026, the boards of Gamma Communications plc ("Gamma" or the "Company") and Bradbury Bidco Limited ("Bidco"), a newly incorporated entity formed by funds managed and/or advised by Epiris GP III Limited and its affiliates, announced that they had reached agreement on the terms of a recommended cash offer by Bidco for the entire issued and to be issued ordinary share capital of Gamma (the "Acquisition"), for cash consideration of 1,120 pence per Gamma Share (the "Acquisition Price").

On 25 September 2026, Gamma published a scheme document relating to the Acquisition (the "Scheme Document"), including notices convening the Court Meeting and the General Meeting (together, the "Meetings") to be held on Tuesday 20 October 2026.

The level of votes cast to date in respect of the Meetings has been materially lower than recent annual general meetings of Gamma. To date, proxy votes have been received in respect of less than 40 per cent. of the Gamma Shares eligible to be voted at the Meetings, and the Company hopes to see this level of participation increase. The Board of Gamma believes that the current level of participation is due, in large part, to a significant proportion (approximately 50 per cent) of the economic interests in the Company being held by merger arbitrage funds which have only recently established their positions. The Board therefore believes that additional time should be allowed for the Gamma Shares underlying those positions, amongst others, to be voted. Accordingly, the Gamma Board have decided to adjourn the Meetings to Monday 2 November 2026. 

Bidco also confirms that the Acquisition Price represents its final offer for the entire issued and to be issued ordinary share capital of Gamma.*

The Gamma Board confirms that it is not in discussions with any other parties in respect of a potential competing offer for Gamma. Bidco and Gamma have submitted all filings required in connection with the antitrust and regulatory conditions set out in the Scheme Document, with German merger control clearance having been received. It is now expected the Scheme to become Effective in Q1 2027 (rather than the first half of 2027 as previously anticipated).

*The Acquisition Price and the financial terms of the Acquisition are final and will not be increased, save that Bidco reserves the right to increase the Acquisition Price and/or otherwise improve the terms of the Acquisition: (i) if there is an announcement on or after the date of this Announcement of a possible offer or a firm intention to make an offer (including a partial offer involving the acquisition or consolidation of control (as defined in the Code)) for Gamma by any third party (whether identified or not); or (ii) in wholly exceptional circumstances with the consent of the Panel. If after the date of this announcement Gamma declares, makes or pays any dividend or distribution or other return of capital to its shareholders, Bidco will make an equivalent reduction to the Acquisition Price.

This announcement is made by Gamma with the consent of Bidco.

Adjournment of Court Meeting and General Meeting

The Gamma Directors have agreed that the chair of the Meetings will use the discretion available to the chair to adjourn the Meetings to afford Gamma Shareholders more time to consider this Announcement, in particular that Bidco has now confirmed the Acquisition Price represents its final* offer, and decide whether or not to submit or change their votes. At the Meetings on Tuesday 20 October 2026, the only business to be dealt with will be to adjourn the Meetings. Accordingly, the Gamma Directors recommend that Gamma Shareholders do not attend the Meetings on Tuesday 20 October 2026.

The Court Meeting will be adjourned to Monday 2 November 2026 at 8.30 a.m. and the General Meeting will be adjourned to Monday 2 November 2026 at 8.45 a.m. (or as soon thereafter as the Court Meeting concludes or is further adjourned), respectively, at the offices of Investec Bank plc at 30 Gresham Street, London, EC2V 7QP.

As previously announced, the Gamma Directors unanimously recommend that the Scheme Shareholders vote or procure votes in favour of the Scheme at the Court Meeting and the Gamma Shareholders vote or procure votes in favour of the Resolution to be proposed at the General Meeting (or, if Bidco exercises its right to implement the Acquisition by way of a Takeover Offer, that Gamma Shareholders accept such offer). All the Gamma Directors who hold Gamma Shares (in a personal capacity or through a nominee) have irrevocably voted in favour in respect of their own beneficial holdings (and their connected persons), amounting, in aggregate, to 114,824 Gamma Shares (representing, in aggregate, approximately 0.13 per cent. of the Gamma Shares (excluding treasury shares) in issue on 24 September 2026, being the last Business Day prior to publication of the Scheme Document).

In respect of each Meeting, the relevant Forms of Proxy (or electronic appointments) should be received as soon as possible and in any event no later than the relevant time set out below:

·    PINK Form of Proxy for the Court Meeting: 8.30 a.m. on Thursday 29 October 2026; and

·    WHITE Form of Proxy for the General Meeting: 8.45 a.m. on Thursday 29 October 2026,

or, in the case of a further adjourned Meeting, not later than 48 hours (excluding non-Business Days) before the time fixed for such further adjourned Meeting.

If the PINK Form of Proxy for use at the Court Meeting is not received by the time and date set out above, it may be handed to the Chair of the Court Meeting or to a representative of MUFG Corporate Markets before the commencement of the adjourned Court Meeting. However, if the WHITE Form of Proxy for the General Meeting is not received by MUFG Corporate Markets by the time and date set out above, it will be invalid.

Action to be taken

As further detailed in the Scheme Document, to become Effective the Scheme will require, among other things, the approval of the requisite majorities of Scheme Shareholders at the Court Meeting and the passing of the Resolution by Gamma Shareholders at the General Meeting.

IT IS IMPORTANT THAT, FOR THE COURT MEETING IN PARTICULAR, AS MANY VOTES AS POSSIBLE ARE CAST SO THAT THE COURT MAY BE SATISFIED THAT THERE IS A FAIR AND REASONABLE REPRESENTATION OF THE OPINION OF THE SCHEME SHAREHOLDERS. YOU ARE THEREFORE STRONGLY ENCOURAGED TO COMPLETE, SIGN AND RETURN YOUR FORMS OF PROXY (OR APPOINT A PROXY ELECTRONICALLY) AS SOON AS POSSIBLE AND, IN ANY EVENT, BEFORE THE DEADLINES STATED ABOVE.

Gamma Shareholders who DO NOT wish to change their voting instructions

Gamma Shareholders who have already submitted Forms of Proxy, or who have appointed a proxy electronically, for the Court Meeting and the General Meeting and do not wish to change their voting instructions need take no further action, as their Forms of Proxy (or electronic appointments) will continue to be valid in respect of the adjourned Court Meeting and General Meeting.

Gamma Shareholders who DO wish to change their voting instructions

Gamma Shareholders who have already submitted Forms of Proxy, or who have appointed a proxy electronically, for the Court Meeting and the General Meeting and now wish to change their voting instructions should submit further Forms of Proxy or electronic proxy appointments by following the relevant procedures set out in the Scheme Document.

For assistance with the completion and return of Forms of Proxy, please telephone MUFG Corporate Markets on 0371 664 0321 (within the UK) or on +44 (0) 371 664 0321 (from outside the UK). Calls are charged at the standard geographic rate and will vary by provider. Calls outside the United Kingdom will be charged at the applicable international rate. The helpline is open between 9.00 a.m. and 5.30 p.m., Monday to Friday excluding public holidays in England and Wales. Different charges may apply to calls from mobile telephones and calls may be recorded and randomly monitored for security and training purposes. The helpline cannot provide advice on the merits of the Acquisition nor give any financial, legal or tax advice.

Revised expected timetable of principal events

An updated expected timetable for the Acquisition is set out in the Appendix to this Announcement. Accordingly, the times and dates set out in the expected timetable of principal events in the Scheme Document and Forms of Proxy should be considered amended as set out in the Appendix to this Announcement. Gamma Shareholders should note that, as set out above, the parties now expect the Scheme to become Effective in Q1 2027.

Capitalised terms used but not defined in this announcement (the "Announcement") have the meanings given to them in the Scheme Document, unless the context requires otherwise. All references to times in this Announcement are to London, United Kingdom times unless stated otherwise.

Enquiries:

Bird & Bird LLP are retained as legal adviser to Gamma in connection with the Acquisition. Latham & Watkins (London) LLP are retained as legal adviser to Epiris and Bidco in connection with the Acquisition.

Important Notices

Goldman Sachs International, which is authorised by the UK Prudential Regulation Authority ("PRA") and regulated by the UK Financial Conduct Authority ("FCA") and the PRA in the United Kingdom, is acting exclusively for Epiris and Bidco in connection with the matters set out in this Announcement and for no one else and will not be responsible to anyone other than Epiris and Bidco for providing the protections afforded to its clients or for providing advice in relation to the matters referred to in this Announcement.

Barclays Bank PLC, acting through its Investment Bank ("Barclays"), which is authorised by the PRA and regulated in the United Kingdom by the FCA and the PRA, is acting exclusively for Gamma and no one else in connection with the matters set out in this Announcement and will not be responsible to anyone other than Gamma for providing the protections afforded to clients of Barclays nor for providing advice in relation to any matter referred to in this Announcement.

In accordance with the Code, normal United Kingdom market practice and Rule 14e-5(b) of the Securities Exchange Act 1934 of the United States, Barclays and its affiliates will continue to act as exempt principal trader in Gamma securities on the London Stock Exchange. These purchases and activities by exempt principal traders which are required to be made public in the United Kingdom pursuant to the Code will be reported to a Regulatory Information Service and will be available on the London Stock Exchange website at www.londonstockexchange.com. This information will also be publicly disclosed in the United States to the extent that such information is made public in the United Kingdom.

Q Advisors LLC ("Q Advisors") is authorised and regulated in the United States by Financial Industry Regulatory Authority ("FINRA") and the Securities and Exchange Commission and is acting exclusively for Gamma and no one else in connection with the matters set out in this Announcement and will not be responsible to anyone other than Gamma for providing the protections afforded to clients of Q Advisors nor for providing advice in relation to any matter referred to in this Announcement.

Investec Bank plc ("Investec"), which is authorised in the United Kingdom by the PRA and regulated in the United Kingdom by the FCA and PRA, is acting exclusively for Gamma and for no one else in connection with the matters set out in this Announcement and none of Investec nor any of its affiliates, branches or subsidiaries will be responsible to any person other than Gamma for providing the protections afforded to clients of Investec, nor for providing advice in relation to any matter referred to in this Announcement. Neither Investec nor any of its subsidiaries, branches or affiliates or any of its and their respective directors, officers, employees, representatives or agents owes or accepts any duty, liability or shall be held responsible in any way whatsoever for any direct, indirect or consequential losses (whether in contract, in tort, under statute or otherwise) arising in connection with this Announcement or in connection with or from the use of the contents of this Announcement or reliance on the information contained herein, except to the extent this would be prohibited by law or regulation.

Peel Hunt LLP ("Peel Hunt") is authorised and regulated in the United Kingdom by the FCA and is acting exclusively for Gamma and no one else in connection with the matters set out in this Announcement and will not be responsible to anyone other than Gamma for providing the protections afforded to clients of Peel Hunt nor for providing advice in relation to any matter referred to in this Announcement.

This Announcement is for information purposes only and is not intended to and does not constitute, or form any part of, an offer to sell or subscribe for or any invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Acquisition or otherwise. The Acquisition will be made solely through and on the terms set out in the Scheme Document (or, in the event that the Acquisition is to be implemented by means of a Takeover Offer, the offer document) and the accompanying Forms of Proxy, which contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Acquisition. Any approval, decision or other response to the Acquisition should be made only on the basis of the information in the Scheme Document. Scheme Shareholders are strongly advised to read the formal documentation in relation to the Acquisition.

The statements contained in this Announcement are made as at the date of this Announcement, unless some other time is specified in relation to them, and service of this Announcement shall not give rise to any implication that there has been no change in the facts set forth in this Announcement since such date.

This Announcement contains inside information in relation to Gamma for the purposes of Article 7 of the UK Market Abuse Regulation. The person responsible for arranging the release of this Announcement on behalf of Gamma is Rachael Matzopoulos, Company Secretary. Gamma's Legal Entity Identifier is 213800LAQZXPRIZUEH50.

Overseas Shareholders

This Announcement has been prepared to comply with English law, the UK Market Abuse Regulation, the Disclosure Guidance and Transparency Rules and the Code and the information disclosed may not be the same as that which would have been disclosed if this Announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom.

The laws of the relevant jurisdictions may affect the availability of the Acquisition to persons who are not resident in the United Kingdom. Persons who are not resident in the United Kingdom, or who are subject to laws of any jurisdiction other than the United Kingdom, should inform themselves about, and observe any applicable requirements. Any person (including, without limitation, nominees, trustees and custodians) who would, or otherwise intends to, forward this Announcement, the Scheme Document or any accompanying document to any jurisdiction outside the United Kingdom should refrain from doing so and seek appropriate professional advice before taking any action. In particular, the ability of persons who are not resident in the United Kingdom to vote their Gamma Shares at the Court Meeting or the General Meeting, or to execute and deliver Forms of Proxy appointing another to vote their Gamma Shares in respect of the Court Meeting or the General Meeting on their behalf, may be affected by the laws of the relevant jurisdiction in which they are located.

Any failure to comply with the applicable legal or regulatory requirements may constitute a violation of the laws and/or regulations of any such jurisdiction. To the fullest extent permitted by applicable law, the companies and persons involved in the Acquisition disclaim any responsibility and liability for the violation of such restrictions by any person.

The Acquisition will not be made, directly or indirectly, in or into or by use of the mails or any other means or instrumentality (including, without limitation, telephonic or electronic) of interstate or foreign commerce of, or any facility of a national, state or other securities exchange of, a Restricted Jurisdiction, and the Acquisition will not be capable of acceptance by any such use, means, instrumentality or facility or from within a Restricted Jurisdiction. Accordingly, copies of this Announcement and other formal documentation relating to the Acquisition are not being, and must not be, directly or indirectly, mailed or otherwise forwarded or distributed in, into or from a Restricted Jurisdiction and persons receiving this Announcement (including custodians, nominees and trustees) must not distribute or send it into or from a Restricted Jurisdiction. In the event that the Acquisition is implemented by way of a Takeover Offer and extended into the US, Bidco will do so in satisfaction of the procedural and filing requirements of the US securities laws at that time, to the extent applicable thereto. The Acquisition relates to the shares of a company incorporated in England and it is proposed to be made by means of a scheme of arrangement provided for under English law. The Scheme will relate to the shares of a UK company that is a "foreign private issuer" as defined under Rule 3b-4 under the US Exchange Act. A transaction effected by means of a scheme of arrangement is not subject to the shareholder vote, proxy solicitation and tender offer rules under the US Exchange Act. Accordingly, the Scheme is subject to the disclosure requirements and practices applicable in the UK to schemes of arrangement, which differ from the disclosure requirements and practices of US shareholder vote, proxy solicitation and tender offer rules. Financial information included in the relevant documentation will have been prepared in accordance with accounting standards applicable in the UK and may not be comparable to the financial statements of US companies. However, if Bidco were to elect to implement the Acquisition by means of a Takeover Offer, such Takeover Offer shall be made in compliance with all applicable laws and regulations, including section 14(e) of the US Exchange Act and Regulation 14E thereunder. Such Takeover Offer would be made in the US by Bidco and no one else. In addition to any such Takeover Offer, Bidco, certain affiliated companies and the nominees or brokers (acting as agents) may make certain purchases of, or arrangements to purchase, shares in Gamma outside such Takeover Offer during the period in which such Takeover Offer would remain open for acceptance. Such purchases may occur either in the open market at prevailing prices or in private transactions at negotiated prices. If such purchases or arrangements to purchase are made they would be made outside the United States in compliance with applicable law, including the US Exchange Act.

Gamma and Bidco are both incorporated under United Kingdom law and registered under the laws of England and Wales. Some or all of the officers and directors of Gamma and Bidco respectively, are residents of countries other than the United States. In addition, some of the assets of Gamma and Bidco are located outside the United States. As a result, it may be difficult for US holders of Gamma Shares to enforce their rights and any claim arising out of the US federal laws or to enforce against them a judgment of a US court predicated upon the securities laws of the United Kingdom. US holders of Gamma Shares may not be able to sue a non-US company or its officers or directors in a non-US court for violations of the US securities laws. Further, it may be difficult to compel a non-US company and its affiliates to subject themselves to a US court's judgment.

Forward-looking statements

This Announcement or other documents referred to in this Announcement may contain certain "forward-looking statements" with respect to Gamma, Bidco and Epiris. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as "anticipate", "target", "expect", "estimate", "intend", "plan", "goal", "believe", "will", "may", "should", "would", "could" or other words or terms of similar meaning or the negative thereof. Forward-looking statements include statements relating to the following: (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; (ii) business and management strategies of Epiris and/or Bidco and the expansion and growth of Gamma and potential synergies resulting from the Acquisition; and (iii) the effects of global economic conditions and government regulation on the business of Gamma.

These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or developments to differ materially from those expressed in or implied by such forward-looking statements. These forward-looking statements are based on numerous assumptions regarding present and future strategies and environments. None of Epiris, Bidco or Gamma, nor any of their respective associates, directors, officers, employees or advisers, provides any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this Announcement will actually occur. You are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. All subsequent oral or written forward-looking statements attributable to Epiris, Bidco or Gamma or any person acting on their behalf are expressly qualified in their entirety by the cautionary statement above. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Announcement. Epiris, Bidco and Gamma assume no obligation to update publicly or revise forward-looking or other statements contained in this Announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

Publication on website

In accordance with Rule 26.1 of the Code, a copy of this Announcement will be made available (subject to certain restrictions relating to persons resident in Restricted Jurisdictions), free of charge, on Gamma's website at https://gammagroup.co/company/investors/disclaimer-content/ and on Bidco's website at https://www.epiris.co.uk/media/gamma-offer/ by no later than 12:00 noon on the Business Day following the date of this Announcement. Neither the contents of this website nor the content of any other website accessible from hyperlinks on such websites is incorporated into, or forms part of, this Announcement.

Electronic communications

Please be aware that addresses, electronic addresses and certain information provided by Gamma Shareholders, persons with information rights and other relevant persons for the receipt of communications from Gamma may be provided to Bidco during the Offer Period as required under section 4 of Appendix 4 of the Code.

Disclosure requirements of the Code

Under Rule 8.3(a) of the Code, any person who is interested in 1 per cent. or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the Offer Period and, if later, following the announcement in which any securities exchange offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of: (i) the offeree company and (ii) any securities exchange offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 p.m. on the 10th Business Day (as defined in the Code) following the commencement of the Offer Period and, if appropriate, by no later than 3.30 p.m. on the 10th Business Day (as defined in the Code) following the announcement in which any securities exchange offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1 per cent. or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of: (i) the offeree company and (ii) any securities exchange offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 p.m. on the Business Day (as defined in the Code) following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror, and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the Offer Period commenced and when any offeror was first identified. You should contact the Takeover Panel's Market Surveillance Unit on +44 (0) 20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.

General

If you are in any doubt about the contents of this Announcement or the action you should take, you are recommended to seek your own independent financial advice immediately from your stockbroker, bank manager, solicitor, accountant or independent financial adviser duly authorised under FSMA if you are resident in the United Kingdom or, if not, from another appropriately authorised independent financial adviser.

The Acquisition is subject to English law, the jurisdiction of the Court, and the applicable requirements of the Code, the Panel, the London Stock Exchange, the FCA, the UK Listing Rules and the Registrar of Companies.

APPENDIX

REVISED EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Notes:

(1)     PINK Forms of Proxy for the adjourned Court Meeting should be received by MUFG Corporate Markets before 8.30 a.m. on Thursday 29 October 2026, being 48 hours (excluding non-Business Days) before the adjourned Court Meeting, or, if the Court Meeting is further adjourned, not later than 48 hours (excluding non-Business Days) before the time fixed for the holding of the further adjourned meeting. PINK Forms of Proxy not so received may be handed to the Chair or a representative of MUFG Corporate Markets before the commencement of the adjourned Court Meeting.

(2)     WHITE Forms of Proxy for the adjourned General Meeting must be received by MUFG Corporate Markets before 8.45 a.m. on Thursday 29 October 2026 in order for it to be valid, being 48 hours (excluding non-Business Days) before the adjourned General Meeting, or, if the General Meeting is further adjourned, not later than 48 hours (excluding non-Business Days) before the time fixed for the holding of the further adjourned meeting. WHITE Forms of Proxy cannot be handed to the Chair or a representative of MUFG Corporate Markets at the General Meeting.

(3)     Only those Scheme Shareholders (in the case of the Court Meeting) and Gamma Shareholders (in the case of the General Meeting) on the register of members of Gamma at 6.00 p.m. on Thursday 29 October 2026, being two days (excluding non-Business Days) before the adjourned Meetings, will be entitled to attend and vote. If a Meeting is further adjourned, only those Scheme Shareholders (in the case of the Court Meeting) and Gamma Shareholders (in the case of the General Meeting) on the register of members of Gamma at 6.00 p.m. on the day which is two days (excluding non-Business Days) before the further adjourned meeting will be entitled to attend and vote.

(4)     The General Meeting will commence at the stated time or as soon thereafter as the Court Meeting concludes or is further adjourned.

(5)     These times and dates are indicative only and will depend on, among other things, the date upon which (i) the Conditions are satisfied or (where applicable) waived; (ii) the Court sanctions the Scheme; and (iii) the Court Order sanctioning the Scheme is delivered to the Registrar of Companies. Gamma will give adequate notice of the date and time of the Sanction Hearing, once known, by issuing an announcement through a Regulatory Information Service. If the expected date of the Sanction Hearing is changed, Gamma will give adequate notice of the change by issuing an updated announcement through a Regulatory Information Service.

(6)     This is the last date by which the Scheme must be implemented unless Bidco and Gamma, with the prior consent of the Panel and, if required, the approval of the Court, agree in writing a later date.